Auxilium On a Roll ...
Health Care: Drugs
Biocryst Pharmaceuticals (BCRX: NASDAQ)
$3.11 0.19 | 6.51%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 2.41 | 0.58 | 0.98 |
| Price to Sales (TTM) | 5.43 | 4.62 | 1.42 |
| Price to Book (MRQ) | 6.20 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 6.20 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -2.90 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 124.90 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -68.50 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -2.21 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -50.11 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.00 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.30 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 1.30 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 1.30 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -91.36 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -55.60 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -1.89 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -55.60 | 5.30 | 7.00 |
| Return on Assets (TTM) | -62.40 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -28.20 | 2.20 | 2.50 |
| Return on Investment (TTM) | -94.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -51.30 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 352,387.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -666,320.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 1.70 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | -2.20 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.30 | 0.40 | 0.40 |
Portfolios with BCRX
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- Usertech
- Userrio grande
- UserDebbie0913 Portfolio 1
- UserPART 7 JPMorgan 28th Annual...
- UserSolana Partners
- UserLatest 2009
- ContributorFast Money's 3 Buys & 4...
- User10 shots
- ContributorCramer's Healthcare Stock Buys
Latest BCRX Headlines from TheStreet
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- Biotech Stock Mailbag: Vivus, Chelsea, BioCryst 02.17.12 | 05:02 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- Biocryst's Gout Drug Fails to Impress 10.05.11 | 11:10 am
- Dendreon's Blowup Spreads Across Biotech 08.04.11 | 10:08 am
- Biotech Stock Mailbag: Vivus 09.24.10 | 07:09 am
- BioCryst Tripped Up by Downgrade 09.23.10 | 04:09 pm
- Savient: Drug Approval or Another Delay? 09.10.10 | 08:09 am
- Biotech Calendar: Key Dates for September 09.01.10 | 07:09 am
- BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 04.28.10 | 06:04 pm
Press Releases for BCRX
- BioCryst To Present At Two Upcoming Investor Conferences - Business Wire 05.22.12 | 06:05 am
- BioCryst Provides Corporate Update And Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 06:05 am
- BioCryst To Report First Quarter 2012 Financial Results On May 7, 2012 - Business Wire 04.25.12 | 06:04 am
- BioCryst To Present At Two Upcoming Investor Conferences - Business Wire 02.23.12 | 06:02 am
- BioCryst Reports Fourth Quarter And Full Year 2011 Financial Results - Business Wire 02.16.12 | 06:02 am
- BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C - Business Wire 02.15.12 | 06:02 am
- BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012 - Business Wire 02.06.12 | 06:02 am
- Nancy Hutson Appointed To BioCryst’s Board Of Directors - Business Wire 01.19.12 | 06:01 am
- BioCryst Announces Positive Results From Its Ongoing BCX4208 Phase 2B Study In Patients With Gout - Business Wire 01.08.12 | 05:01 pm
- BioCryst Pharmaceuticals Presents New BCX4208 Gout Data At The 2011 ACR/ARHP Annual Scientific Meeting - Business Wire 11.08.11 | 06:11 am
Partner Headlines for BCRX
- Today's Market News To Trade On: 5 Stocks Making News - Seeking Alpha 03.23.12 | 08:03 am
- UPDATE: Bird Flu Found in the Netherlands - Benzinga 03.19.12 | 01:03 pm
- Noteworthy Institutional 5% Ownership Filings Last Week - Seeking Alpha 03.19.12 | 09:03 am
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- Biotechs And Their Trials By Fire - Seeking Alpha 11.07.11 | 09:11 am
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 11.04.11 | 09:11 am
- BioCryst Pharmaceuticals To Present New Peramivir Data at the 51st Annual ICAAC Meeting - Benzinga 09.17.11 | 06:09 pm
- A Bullish Speculative Options Bet and a Bearish One - Seeking Alpha 06.30.11 | 09:06 am
- 7 Speculative Healthcare Stocks to Rejuvenate Your Portfolio - Seeking Alpha 05.31.11 | 08:05 am
- UPDATE 1-BioCryst says influenza drug lowers virus concentration - Reuters 01.13.11 | 08:01 am
